InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
March 08 2022 - 7:30AM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical
company developing anti-inflammatory therapeutics by targeting the
complement system, announced that final data from the Company’s
Phase IIa open-label study with vilobelimab in patients with
pyoderma gangrenosum (PG) will be presented at the
2022
American Academy of Dermatology Association (AAD) Annual
Meeting, being held March 25-29 in Boston, MA USA.
Afsaneh Alavi, M.D., Associate Professor of
Dermatology at the Mayo Clinic and Coordinating Principal
Investigator of the study, will give a late-breaker oral
presentation entitled, “Anti-C5a antibody Vilobelimab (IFX-1)
treatment in patients with ulcerative pyoderma gangrenosum: Phase
2, open-label dose escalation trial,” on March 26th at 11:20 AM
EDT.
Dr. Alavi will present updated results in her
presentation, which will include PG ulcer status during the
observational period from the third cohort, along with other
outcome measures.
Positive data from the third cohort of patients
in this study were announced in October 2021.
About Vilobelimab
Vilobelimab is a first-in-class monoclonal
anti-human complement factor C5a antibody, which highly and
effectively blocks the biological activity of C5a and demonstrates
high selectivity towards its target in human blood. Thus,
vilobelimab leaves the formation of the membrane attack complex
(C5b-9) intact as an important defense mechanism, which is not the
case for molecules blocking the cleavage of C5. Vilobelimab has
been demonstrated in pre-clinical studies to control the
inflammatory response driven tissue and organ damage by
specifically blocking C5a as a key “amplifier” of this response.
Vilobelimab is believed to be the first monoclonal anti-C5a
antibody introduced into clinical development. Over 300 people have
been treated with vilobelimab in completed clinical trials, and the
antibody has been shown to be well tolerated. Vilobelimab is
currently being developed for various indications, including
hidradenitis suppurativa, and has recently reported positive Phase
II results in ANCA-associated vasculitis and pyoderma gangrenosum.
Vilobelimab is in Phase III development for the treatment of
critically ill COVID-19 patients and in Phase II development for
patients suffering from cutaneous squamous cell carcinoma
(cSCC).
About InflaRx N.V.
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
technology to discover and develop first-in-class or best-in-class,
potent and specific inhibitors of C5a and C5aR. Complement C5a and
C5aR are powerful inflammatory mediators involved in the
progression of a wide variety of autoimmune and other inflammatory
diseases. InflaRx was founded in 2007, and the group has offices
and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor,
MI, USA. For further information, please visit www.inflarx.com.
Contacts:InflaRx
N.V.Jordan Zwick – Chief Strategy OfficerJason Stewart –
Strategy & Investor RelationsEmail: IR@inflarx.deTel: +1
917-338-6523
MC Services AGKatja Arnold,
Laurie Doyle, Andreas JungferEmail: inflarx@mc-services.euEurope:
+49 89-210 2280US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “believe,” “estimate,”
“predict,” “potential” or “continue” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and may include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, our ongoing and planned preclinical
development and clinical trials; the impact of the COVID-19
pandemic on the Company; the timing and our ability to commence and
conduct clinical trials; potential results from current or
potential future collaborations; our ability to make regulatory
filings, obtain positive guidance from regulators, and obtain and
maintain regulatory approvals for our product candidates; our
intellectual property position; our ability to develop commercial
functions; expectations regarding clinical trial data; our results
of operations, cash needs, financial condition, liquidity,
prospects, future transactions, growth and strategies; the industry
in which we operate; the trends that may affect the industry or us
and the risks, uncertainties and other factors described under the
heading “Risk Factors” in InflaRx’s periodic filings with the
Securities and Exchange Commission. These statements speak only as
of the date of this press release and involve known and unknown
risks, uncertainties and other important factors that may cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Given these
risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024